Is Ambarella Inc (AMBA) a risky stock?
As of July 30, 2026, Clavix grades Ambarella Inc (AMBA) D- for risk, a composite score of 38 out of 100 on an A+ to F scale, which puts AMBA in the "elevated risk" band. The grade is a risk read for educational purposes, not a buy or sell recommendation.
Grade as of July 30, 2026. Clavix regrades every trading day.
The five risk dimensions behind AMBA's grade
Each Clavix grade is a composite of five independent reads. Higher is safer. Here is how AMBA scores on each, as of July 30, 2026.
What's moving AMBA's risk right now
Company-specific signals Clavix flags behind AMBA's current grade, drawn from recent news and filings as of July 30, 2026.
Ambarella signed an $800M, 10-year deal with Hanwha to co-develop edge AI chips, averaging about $80M per year. The agreement backs Ambarella's low-power chip technology with a major partner and locks in long-term revenue.
Shares have pulled back nearly 29% from their 52-week high even after Ambarella announced its $800M Hanwha partnership. Analysts' average price target still points to roughly 47% upside from current levels.
Recent AMBA news
The latest headlines Clavix ingested for Ambarella Inc, newest first. These feed the news-sentiment dimension of AMBA's grade.
What a D- grade means
On the Clavix A+ to F scale, AMBA's composite of 38 falls in the D band (35–49), read as "elevated risk." The scale is fixed, so the meaning never moves.
This page is generated from Clavix's own risk model and is for educational purposes only. It is not investment advice or a recommendation to buy or sell AMBA or any security. Grades are risk indicators, not predictions of return. Data may be delayed.